Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year
13. Mai 2024 08:00 ET | Exagen Inc.
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31,...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen Announces Campaign for Lupus Awareness Month
06. Mai 2024 16:05 ET | Exagen Inc.
CARLSBAD, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen to Announce First Quarter 2024 Results on May 13, 2024
30. April 2024 16:05 ET | Exagen Inc.
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen Inc. Announces Changes to the Board of Directors
26. April 2024 08:30 ET | Exagen Inc.
CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors. Exagen is...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
18. März 2024 08:00 ET | Exagen Inc.
CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full...
exagen-logo-440x386-1.jpg
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
08. März 2024 09:00 ET | Exagen Inc.
CARLSBAD, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital...
exagen-logo-440x386-1.jpg
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
07. März 2024 16:05 ET | Exagen Inc.
CARLSBAD, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31,...
exagen-logo-440x386-1.jpg
Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
30. Januar 2024 16:05 ET | Exagen Inc.
CARLSBAD, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital...
exagen-logo-440x386-1.jpg
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
07. Januar 2024 12:00 ET | Exagen Inc.
CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for...
exagen-logo-440x386-1.jpg
Exagen Inc. Reports Strong Third Quarter 2023 Results
13. November 2023 16:05 ET | Exagen Inc.
SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended...